Psychedelics are known for inducing altered states of consciousness in humans by fundamentally changing our normal pattern of sensory perception, thought and emotion.
Enveric Biosciences has confirmed it has completed the manufacture of its lead drug candidate – EB-373 – a New Chemical Entity (NCE) designed as a next-generation...
Cybin Inc.
Researchers at Lund University have developed a new measuring technique to understand what happens to the neurons in rats’ brains when they are given psychedelics.
PharmAla Biotech Holdings has announced that it has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia.
The final cohort of patients has been dosed in Cybin’s Dosing Phase 2 Trial investigating CYB003 – an investigational deuterated analogue of psilocybin – as a...
MGC Pharmaceuticals has received permission to import psilocybin into Slovenia.
A low-cost version of ketamine has shown promising results in its treatment of resistant depression in a double-blind trial.
A group of doctors are urging researchers to look at psychedelics to ease the often overwhelming distress faced by women with late-stage gynaecological cancers.
With an explosion in research looking at psychedelic therapy for a number of mental health conditions, FDA approval for MDMA-assisted psychotherapy for PTSD is anticipated for...